Teva Pharmaceutical Industries (NYSE:TEVA) Releases Q1 2025 Earnings Guidance

Teva Pharmaceutical Industries (NYSE:TEVA) issued an update on its first quarter 2025 earnings guidance on Friday morning. The company provided EPS guidance of 0.520-0.520 for the period, compared to the consensus EPS estimate of 0.480. The company issued revenue guidance of $4.0 billion-$4.0 billion, compared to the consensus revenue estimate of $4.0 billion. Teva Pharmaceutical Industries also updated its FY 2025 guidance to 2.350-2.650 EPS.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on TEVA. UBS Group cut their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. Bank of America reduced their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, March 6th. StockNews.com downgraded Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Thursday. Piper Sandler boosted their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, January 17th. Finally, Barclays cut their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and a consensus target price of $23.43.

Teva Pharmaceutical Industries Trading Down 2.8 %

TEVA stock opened at $15.06 on Friday. Teva Pharmaceutical Industries has a 52 week low of $12.51 and a 52 week high of $22.80. The company has a market cap of $17.07 billion, a price-to-earnings ratio of -10.38, a PEG ratio of 1.44 and a beta of 0.82. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The business has a fifty day simple moving average of $17.21 and a 200-day simple moving average of $18.12.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, equities research analysts expect that Teva Pharmaceutical Industries will post 2.5 EPS for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.